Status:
COMPLETED
Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A
Lead Sponsor:
Bayer
Conditions:
Hematologic Disease
Blood Coagulation Disorders
Eligibility:
MALE
14-29 years
Brief Summary
Understanding how often the bleeding events occur in the subjects who voluntarily decide to switch from prophylaxis to on-demand and in those subjects who remain on prophylaxis. Also look into the con...
Eligibility Criteria
Inclusion
- Severe hemophilia A (\<2%)
- For subjects who elect staying on Prophylaxis only: Have been on continuous prophylactic treatment for the past 5 years prior to study entry
- For subjects who elect switching to on-demand only: Have been on continuous prophylactic treatment for the past 5 years, but may have been on intermediate or reduced prophylaxis for the 1-12 months prior to study entry
- For subjects currently on-demand: a retrospective arm of subjects who have been on continuous prophylactic treatment for at least 5 years and switched to on-demand treatment between 13 and 24 months prior to study entry
- Current treatment with rFVIII
Exclusion
- Other known hematological / bleeding disorders other than hemophilia A
- Participating on another study that may have an impact on bleeding or the objectives of this study
- Known alcohol and drug abuse
Key Trial Info
Start Date :
December 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00782470
Start Date
December 1 2007
End Date
November 1 2010
Last Update
November 3 2014
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Duarte, California, United States, 91010
2
Denver, Colorado, United States, 80262
3
Peoria, Illinois, United States, 61614
4
Jefferson City, Missouri, United States, 65109